Appili Therapeutics Inc. (APLI.TO)
CAD 0.04
(-12.5%)
CAD 0.04
(-12.5%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -8.05 Million CAD | -1.38% |
| 2022 | -7.91 Million CAD | 67.93% |
| 2021 | -24.67 Million CAD | -51.44% |
| 2020 | -16.29 Million CAD | -165.75% |
| 2019 | -6.13 Million CAD | 14.42% |
| 2018 | -7.16 Million CAD | -90.18% |
| 2017 | -3.76 Million CAD | 0.05% |
| 2016 | -3.76 Million CAD | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q1 | -2.78 Million CAD | 100.0% |
| 2023 Q4 | -2.41 Million CAD | -1658.44% |
| 2023 FY | -8.02 Million CAD | -1.38% |
| 2023 Q3 | 155.07 Thousand CAD | 137.3% |
| 2023 Q2 | -415.68 Thousand CAD | 81.37% |
| 2023 Q1 | -2.23 Million CAD | -0.96% |
| 2022 Q1 | -2.06 Million CAD | 5.45% |
| 2022 Q4 | -2.2 Million CAD | 6.65% |
| 2022 FY | -7.91 Million CAD | 67.93% |
| 2022 Q3 | -2.36 Million CAD | -103.18% |
| 2022 Q2 | -1.16 Million CAD | 43.55% |
| 2021 Q3 | -2.98 Million CAD | 72.96% |
| 2021 FY | -24.67 Million CAD | -51.44% |
| 2021 Q1 | -7.32 Million CAD | -47.98% |
| 2021 Q2 | -11.04 Million CAD | -50.85% |
| 2021 Q4 | -2.18 Million CAD | 26.92% |
| 2020 FY | -16.29 Million CAD | -165.75% |
| 2020 Q1 | -2.59 Million CAD | -106.36% |
| 2020 Q4 | -4.94 Million CAD | -16.69% |
| 2020 Q3 | -4.24 Million CAD | -71.96% |
| 2020 Q2 | -2.46 Million CAD | 5.11% |
| 2019 Q3 | -1.14 Million CAD | -2.99% |
| 2019 Q2 | -1.11 Million CAD | 41.01% |
| 2019 Q1 | -1.88 Million CAD | -51.85% |
| 2019 FY | -6.13 Million CAD | 14.42% |
| 2019 Q4 | -1.25 Million CAD | -9.91% |
| 2018 FY | -7.16 Million CAD | -90.18% |
| 2018 Q4 | -1.24 Million CAD | -7.97% |
| 2018 Q1 | -680.26 Thousand CAD | 63.85% |
| 2018 Q2 | -1.29 Million CAD | -91.02% |
| 2018 Q3 | -1.15 Million CAD | 11.46% |
| 2017 FY | -3.76 Million CAD | 0.05% |
| 2017 Q4 | -1.88 Million CAD | 17.06% |
| 2017 Q3 | -2.26 Million CAD | 0.0% |
| 2016 FY | -3.76 Million CAD | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Eupraxia Pharmaceuticals Inc. | -36.89 Million CAD | 78.182% |
| Helix BioPharma Corp. | -9.37 Million CAD | 14.095% |
| Microbix Biosystems Inc. | -2.73 Million CAD | -194.186% |
| Medicenna Therapeutics Corp. | -19.66 Million CAD | 59.059% |
| Satellos Bioscience Inc. | -15.46 Million CAD | 47.939% |
| Oncolytics Biotech Inc. | -33.79 Million CAD | 76.177% |
| Sernova Corp. | -41.13 Million CAD | 80.428% |